BIO vs TECH vs BRKR Stock Comparison

Bio-Rad Laboratories, Bio-Techne and Bruker Prices as of Nov 13, 2026 Peers: Industry group
TECH BIO-TECHNE Corp
$72.80 +0.4% 1M +19.8% 1Y
Market cap
$11.42B
P/E
66.4x
Revenue (TTM)
$1.23B
Div. yield
0.00%
Life Sciences Tools Healthcare
4 wins
BRKR Bruker Corp
$61.59 +10.8% 1M +47.4% 1Y
Market cap
$9.13B
P/E
–
Revenue (TTM)
$3.51B
Div. yield
0.00%
Life Sciences Tools Healthcare
4 wins

Head to Head

12 decided of 12

Bio-Techne leads on 4 of the 12 questions below (Bio-Techne 4, Bio-Rad Laboratories 4, Bruker 4). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionBIOTECHBRKRLeader
Larger companyMarket capitalisation $9.79B $11.42B $9.13B TECH
Cheaper on earningsLower P/E, profitable companies only 9.6x 66.4x -54.6x BIO
Cheaper on forward earningsLower price / next fiscal year consensus EPS 36.0x 33.4x 28.0x BRKR
Faster revenue growthRevenue growth, trailing twelve months +1.4% +0.9% +2.2% BRKR
More profitableNet margin, trailing twelve months 39.5% 14.0% -4.8% BIO
Better return on capitalReturn on invested capital -0.6% 7.8% -1.7% TECH
Less leveragedLower net debt / EBITDA — -0.4x 10.0x TECH
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% TECH
Better 1-year returnPrice return, last 12 months +15.5% +19.8% +47.4% BRKR
Better 5-year returnAnnualised price return, 5 years -13.5%/yr -10.4%/yr -5.7%/yr BRKR
Less volatileAnnualised volatility, 1 year 36.5% 42.8% 62.4% BIO
Higher overall scoreMean of the five percentile scores vs peers 70/100 68/100 48/100 BIO

Percentile Scorecard

BIOTECHBRKR

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisBIOTECHBRKR
Valuation 85 #38 of 243 62 #92 of 243 69 #77 of 243
Growth 48 #120 of 228 56 #102 of 228 18 #187 of 228
Profitability 70 #67 of 222 94 #15 of 222 63 #82 of 222
Financial Health 66 #85 of 248 79 #53 of 248 19 #200 of 248
Shareholder Returns 80 #32 of 158 47 #84 of 158 69 #50 of 158
Overall 70 68 48
  • BIO ranked among 252 companies in Medical Devices and Diagnostics
  • TECH ranked among 252 companies in Medical Devices and Diagnostics
  • BRKR ranked among 252 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodBIOTECHBRKRSPY
1 month +1.0%+0.4%+10.8% -2.0%
3 months +2.8%+0.6%+6.7% -2.8%
6 months +47.9%+68.1%+43.6% +2.0%
Year to date +20.8%+23.8%+30.7% +10.6%
1 year +15.5%+19.8%+47.4% +12.2%
3 years +19.1%+20.6%-0.1% +68.1%
3 years, per year +6.0%+6.5%0.0% +18.9%
5 years -51.6%-42.3%-25.4% +61.4%
5 years, per year -13.5%-10.4%-5.7% +10.1%
10 years +119.6%+173.4%+169.3% +248.5%
10 years, per year +8.2%+10.6%+10.4% +13.3%

Risk

MeasureBIOTECHBRKRSPY
Volatility, 1Y 36.5%42.8%62.4% 13.6%
Downside volatility, 1Y 35.6%43.2%59.9% 13.9%
Beta vs S&P 500, 1Y 0.750.631.75 1.00
Return / volatility, 1Y 0.430.460.76 0.90
Max drawdown, 5Y -72.2%-66.5%-68.9% -25.4%
From 52-week high -6.2%-0.1%-7.4% -3.2%
52-week high $390.34$72.84$66.54 $779.14
52-week low $241.71$43.30$32.76 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleBIOTECHBRKR
P/E now vs peer median 9.6xmedian 26.5x 66.4xmedian 26.5x -56.1xmedian 26.5x
P/S now vs peer median 3.8xmedian 2.7x 9.3xmedian 2.7x 2.7xmedian 2.7x
EV/EBITDA now vs peer median —median 18.4x 33.4xmedian 18.4x 69.3xmedian 18.4x
P/FCF now vs peer median 29.9xmedian 25.4x 37.1xmedian 25.4x 38.4xmedian 25.4x
P/B now vs peer median 1.3xmedian 2.5x 5.3xmedian 2.5x 4.1xmedian 2.5x
PEG now vs peer median 0.09median 0.98 -6.27median 0.98 1.57median 0.98

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsBIOTECHBRKR
Revenue $2.59B $1.23B $3.51B
Gross profit $1.33B $807.58M $1.67B
Operating income -$61.90M $240.84M -$69.80M
Net income $1.02B $171.97M -$115.70M
Free cash flow $329.10M $308.20M $244.70M
R&D $265.80M $96.87M $387.20M
EPS (diluted) $37.96 $1.09 $-1.10
Cash & equivalents $465.30M $350.04M $119.70M
Total debt $1.20B $200.00M $1.71B
Shares (diluted) 26.95M 157.93M 152.50M
Enterprise value $3.40B $10.42B $8.39B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricBIOTECHBRKR
P/E 9.6x 66.4x -56.1x
P/FCF 29.9x 37.1x 38.4x
P/Operating cash flow 21.0x 33.9x 27.5x
P/S 3.8x 9.3x 2.7x
P/B 1.3x 5.3x 4.1x
P/Tangible book 1.3x 6.1x 4.2x
EV/EBITDA – 33.4x 69.3x
EV/EBIT -151.6x 46.9x -157.6x
EV/Revenue 3.6x 9.2x 3.1x
EV/FCF 28.5x 36.6x 45.0x
EV/Operating cash flow 20.1x 33.4x 32.2x
PEG (3Y EPS CAGR) 0.09 -6.27 1.57

Growth

14 metrics
MetricBIOTECHBRKR
Revenue growth (1Y) 1.4% 0.9% 2.2%
Revenue CAGR (3Y) -1.6% 2.4% 7.6%
Gross profit growth (1Y) -0.6% 1.5% 3.2%
Gross profit CAGR (3Y) -3.0% 1.4% 4.9%
Operating income growth (1Y) -127.6% 119.1% -209.1%
Operating income CAGR (3Y) -29.5% -6.9% -29.1%
Net income growth (1Y) 251.3% 120.5% -390.3%
Net income CAGR (3Y) 103.5% -11.3% -33.1%
EPS growth (1Y) 251.2% 118.3% -602.7%
EPS CAGR (3Y) 107.7% -10.6% -35.8%
Operating cash flow growth (1Y) -4.8% 34.4% 262.5%
Operating cash flow CAGR (3Y) 7.8% 9.4% 2.6%
Free cash flow growth (1Y) -2.3% 37.6% 2,408%
Free cash flow CAGR (3Y) 13.6% 12.7% 5.9%

Profitability

14 metrics
MetricBIOTECHBRKR
Gross margin 51.3% 65.8% 47.7%
EBITDA margin – 27.5% 4.5%
Operating margin -2.4% 19.6% -2.0%
Pretax margin 50.9% 18.5% -2.0%
Net margin 39.5% 14.0% -4.8%
FCF margin 12.7% 25.1% 7.0%
Operating cash flow margin 18.1% 27.5% 9.7%
Return on equity 13.8% 7.7% -4.9%
Return on assets 9.7% 6.3% -2.0%
Return on invested capital -0.6% 7.8% -1.7%
Return on capital employed -0.6% 10.7% -1.5%
Asset turnover 0.2x 0.5x 0.6x
Cash conversion (OCF / net income) 0.5x 2.0x -3.0x
Stock comp / revenue 2.4% 1.6% –

Financial Health

11 metrics
MetricBIOTECHBRKR
Debt / assets 11.2% 7.6% 29.4%
Debt / equity 0.2x 0.1x 0.7x
Net debt / EBITDA – -0.4x 10.0x
Debt / FCF 3.7x 0.6x 7.0x
Liabilities / assets 29.5% 17.9% 60.4%
Equity / assets 70.5% 82.1% 39.6%
Interest coverage -1.3x 27.2x -1.2x
Current ratio 3.2x 2.3x 1.8x
Quick ratio 2.2x 1.5x 0.7x
Cash ratio 1.7x 1.0x 0.1x
Altman Z-score 3.41 16.15 –

Shareholder Returns

7 metrics
MetricBIOTECHBRKR
Dividend yield – 0.5% 0.3%
Net buyback yield 0.7% -0.5% –
Shareholder yield 0.7% 0.1% 0.3%
Payout ratio (earnings) – 29.1% -26.2%
Payout ratio (FCF) – 16.2% 12.4%
Dividend growth (1Y) – -0.2% 32.3%
Dividend CAGR (3Y) – -0.2% 0.9%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusBIOTECHBRKR
Forward P/E 36.0xFY2026 33.4xFY2027 28.0xFY2026
EPS, next fiscal year $10.18FY2026 $2.18FY2027 $2.20FY2026
EPS growth, next FY +2.6%FY2026 +13.0%FY2027 +20.2%FY2026
EPS growth, the year after -0.2% +3.2% +5.5%
Revenue, next fiscal year $2.69BFY2026 $1.19BFY2027 $3.76BFY2026
Revenue growth, next FY +4.2%FY2026 -2.1%FY2027 +9.4%FY2026
Revenue growth, the year after -7.4% +13.5% +2.7%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersBIOTECHBRKR
Held by institutions 89.5% 100.0% 93.1%
Institutions holding 405 599 418
Change in shares held, QoQ -2.9% -0.6% +3.6%
Institutions buying 177 293 249
Institutions selling 157 241 122
Buyers to sellers 1.13 1.22 2.04

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

BIOTECHBRKR
BIO 1.00 0.39 0.48
TECH 0.39 1.00 0.29
BRKR 0.48 0.29 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, BIO, TECH and BRKR?

Bio-Techne (TECH) is the largest by market capitalisation: Bio-Rad Laboratories (BIO) $9.79B, Bio-Techne (TECH) $11.42B, Bruker (BRKR) $9.13B.

Which stock is cheaper, BIO, TECH and BRKR?

Bio-Rad Laboratories (BIO) trades on the lowest price-to-earnings ratio (Bio-Rad Laboratories (BIO) 9.6x, Bio-Techne (TECH) 66.4x, Bruker (BRKR) -54.6x). On next year's consensus earnings, Bruker (BRKR) is cheapest (Bio-Rad Laboratories (BIO) 36.0x, Bio-Techne (TECH) 33.4x, Bruker (BRKR) 28.0x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Bruker (BRKR) grew revenue fastest over the trailing twelve months: Bio-Rad Laboratories (BIO) +1.4%, Bio-Techne (TECH) +0.9%, Bruker (BRKR) +2.2%.

Which company is more profitable?

Bio-Rad Laboratories (BIO) has the highest net margin (Bio-Rad Laboratories (BIO) 39.5%, Bio-Techne (TECH) 14.0%, Bruker (BRKR) -4.8%). On return on invested capital, Bio-Techne (TECH) leads (Bio-Rad Laboratories (BIO) -0.6%, Bio-Techne (TECH) 7.8%, Bruker (BRKR) -1.7%).

Which stock has performed better?

Over the past year Bruker (BRKR) returned the most: Bio-Rad Laboratories (BIO) +15.5%, Bio-Techne (TECH) +19.8%, Bruker (BRKR) +47.4%. Over five years, Bruker (BRKR) compounded fastest (Bio-Rad Laboratories (BIO) -13.5%/yr, Bio-Techne (TECH) -10.4%/yr, Bruker (BRKR) -5.7%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Bio-Techne (TECH) has the highest dividend yield: Bio-Rad Laboratories (BIO) 0.00%, Bio-Techne (TECH) 0.00%, Bruker (BRKR) 0.00%. Bio-Rad Laboratories (BIO) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Bio-Rad Laboratories (BIO) has been the steadiest (Bio-Rad Laboratories (BIO) 36.5%, Bio-Techne (TECH) 42.8%, Bruker (BRKR) 62.4%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, BIO, TECH and BRKR?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Bio-Techne (TECH) leads on 4. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.